COVID-19 Vaccines: The Current Candidates in Phase III Trials .
OrthoEvidence Journal (OE Journal) - OE Original
OE Journal. 2020;8(18):1As global hopes turn toward vaccination as the only realistic path to herd immunity, several COVID-19 vaccines have moved rapidly through development, with multiple candidates already in phase III trials. These include mRNA platforms from Pfizer–BioNTech and Moderna, viral-vector vaccines from Oxford–AstraZeneca and CanSino, and inactivated vaccines from Sinovac and Sinopharm. Early data suggest encouraging immune responses, but questions remain about long-term safety, durability, manufacturing capacity, and equitable distribution. Even with accelerated review, broad public access is unlikely until mid- to late-2021, underscoring the need to balance speed with rigorous evaluation while preparing for the complex rollout that will follow.
Unlock the Full original article
You have access to 4 more FREE articles this month.
Click below to unlock and view this original article
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
Are you affiliated with one of our partner associations?
Click here to gain complimentary access as part your association member benefits!